Revatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates cellular guanylate cyclase, which in turn increases cyclic guanosine monophosphate concentrations, leading to smooth muscle cell vasorelaxation.
The first-to-market phosphodiesterase 5 (PDE5) inhibitor Revatio (sildenafil; Pfizer) is firmly established within the treatment algorithm as a first-line treatment for pulmonary arterial hypertension (PAH) patients. However, its loss of exclusivity in the US and EU has resulted in much-reduced sales for Pfizer. Further generic erosion in Japan is also expected from Q3 2018. Nevertheless, Revatio is likely to continue to provide a steady, albeit small, revenue stream for Pfizer, especially as physicians increasingly use combination therapies for their pulmonary hypertension (PH) patients.
LIST OF FIGURES
9 Figure 1: Revatio for pulmonary hypertension – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Revatio for pulmonary hypertension
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Revatio for pulmonary hypertension
13 Figure 4: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
5 Table 1: Revatio drug profile
7 Table 2: Revatio pivotal trial data in pulmonary hypertension
14 Table 3: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.